Atara Biotherapeutics, Inc. (0HIY.L)
USD 10.43
(-0.02%)
USD 10.43
(-0.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -265.99 Million USD | 20.05% |
| 2022 | -213.72 Million USD | 2.85% |
| 2021 | -331.11 Million USD | -10.16% |
| 2020 | -296.73 Million USD | -4.52% |
| 2019 | -282.85 Million USD | -24.7% |
| 2018 | -233.33 Million USD | -95.1% |
| 2017 | -120.57 Million USD | -49.59% |
| 2016 | -80.85 Million USD | -39.0% |
| 2015 | -58.4 Million USD | -107.59% |
| 2014 | -28.15 Million USD | -226.98% |
| 2013 | -8.61 Million USD | 4.89% |
| 2012 | -4.09 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -16.54 Million USD | 43.61% |
| 2024 Q1 | -25.1 Million USD | 49.73% |
| 2023 Q1 | -75.01 Million USD | 0.69% |
| 2023 FY | - USD | 20.05% |
| 2023 Q4 | -52.07 Million USD | 22.53% |
| 2023 Q3 | -67.21 Million USD | 1.92% |
| 2023 Q2 | -68.52 Million USD | 8.65% |
| 2022 Q4 | -75.53 Million USD | 9.27% |
| 2022 Q1 | -86.62 Million USD | 7.25% |
| 2022 Q2 | -80.93 Million USD | 6.58% |
| 2022 FY | - USD | 2.85% |
| 2022 Q3 | -83.25 Million USD | -2.87% |
| 2021 Q3 | -82.49 Million USD | -0.99% |
| 2021 Q4 | -93.4 Million USD | -13.22% |
| 2021 Q1 | -76.02 Million USD | 6.95% |
| 2021 FY | - USD | -10.16% |
| 2021 Q2 | -81.68 Million USD | -7.45% |
| 2020 Q4 | -81.69 Million USD | -9.36% |
| 2020 Q1 | -72.74 Million USD | 8.72% |
| 2020 Q2 | -75.89 Million USD | -4.33% |
| 2020 Q3 | -74.7 Million USD | 1.57% |
| 2020 FY | - USD | -4.52% |
| 2019 Q2 | -73.79 Million USD | -11.4% |
| 2019 Q1 | -66.24 Million USD | 19.03% |
| 2019 FY | - USD | -24.7% |
| 2019 Q4 | -79.69 Million USD | -12.62% |
| 2019 Q3 | -70.76 Million USD | 4.11% |
| 2018 Q3 | -59.03 Million USD | -13.76% |
| 2018 Q1 | -42.11 Million USD | -17.64% |
| 2018 FY | - USD | -95.1% |
| 2018 Q4 | -81.81 Million USD | -38.6% |
| 2018 Q2 | -51.89 Million USD | -23.2% |
| 2017 Q1 | -25.95 Million USD | -38.4% |
| 2017 FY | - USD | -49.59% |
| 2017 Q4 | -35.8 Million USD | -13.98% |
| 2017 Q3 | -31.41 Million USD | -13.45% |
| 2017 Q2 | -27.68 Million USD | -6.67% |
| 2016 Q2 | -19.42 Million USD | -13.93% |
| 2016 Q1 | -17.04 Million USD | 21.7% |
| 2016 FY | - USD | -39.0% |
| 2016 Q4 | -18.75 Million USD | 27.34% |
| 2016 Q3 | -25.81 Million USD | -32.9% |
| 2015 FY | - USD | -107.59% |
| 2015 Q2 | -6.1 Million USD | 34.4% |
| 2015 Q1 | -9.31 Million USD | 12.13% |
| 2015 Q4 | -21.77 Million USD | -77.73% |
| 2015 Q3 | -12.24 Million USD | -100.54% |
| 2014 Q2 | -4.53 Million USD | 35.89% |
| 2014 Q4 | -10.59 Million USD | -78.17% |
| 2014 FY | - USD | -226.98% |
| 2014 Q3 | -5.94 Million USD | -31.16% |
| 2014 Q1 | -7.07 Million USD | -107.03% |
| 2013 Q1 | -1.28 Million USD | 0.0% |
| 2013 Q3 | -2.55 Million USD | -87.57% |
| 2013 Q4 | -3.41 Million USD | -33.91% |
| 2013 FY | - USD | 4.89% |
| 2013 Q2 | -1.36 Million USD | -5.84% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -63.071% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2851.883% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 370.702% |
| Perrigo Company plc | 646.2 Million USD | 141.163% |
| Illumina, Inc. | -608 Million USD | 56.25% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.463% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 40.76% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 97.641% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 108.169% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -156.279% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 105.715% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -613.454% |
| Waters Corporation | 1.02 Billion USD | 126.021% |
| Biogen Inc. | 2.37 Billion USD | 111.19% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -204.25% |
| Evolus, Inc. | -41.81 Million USD | -536.204% |
| Adicet Bio, Inc. | -136.53 Million USD | -94.82% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -126.092% |
| bluebird bio, Inc. | -167.16 Million USD | -59.126% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -77.204% |
| FibroGen, Inc. | -261.4 Million USD | -1.757% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 115.861% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -498.598% |
| Homology Medicines, Inc. | -47.75 Million USD | -456.992% |
| Geron Corporation | -174.78 Million USD | -52.188% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -16.603% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -188.879% |
| Myriad Genetics, Inc. | -67.8 Million USD | -292.326% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -163.815% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 47.464% |
| Zoetis Inc. | 3.68 Billion USD | 107.218% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -425.977% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 122.851% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 185.727% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 105.776% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -637.201% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -15.646% |
| Verastem, Inc. | -83.16 Million USD | -219.839% |
| Nektar Therapeutics | -243.1 Million USD | -9.416% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -18.226% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -202.321% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 39.435% |
| OPKO Health, Inc. | -65.51 Million USD | -306.003% |
| Exelixis, Inc. | 196.6 Million USD | 235.297% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 163.926% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 345.557% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -377.073% |
| uniQure N.V. | -253.1 Million USD | -5.096% |
| Imunon, Inc. | -20.78 Million USD | -1179.922% |
| Blueprint Medicines Corporation | -474.61 Million USD | 43.955% |
| Insmed Incorporated | -654.73 Million USD | 59.374% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 158.856% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 23.003% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1119.146% |
| Incyte Corporation | 919.42 Million USD | 128.931% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 47.359% |